Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

NCT03719924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma

Interventions

DRUG: Onivyde
DRUG: Paclitaxel

Sponsor

Federation Francophone de Cancerologie Digestive

Collaborators

[object Object]
[object Object]